Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-Q/A
Source: 0001731122-25-000250
Chunk: 62

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-Q/A
Chunk 62
---
2,000,000 of its Promissory Note into 280,505 of the Company’s Units at a price
per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company’s Units at a price per
Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS
was deemed to be an affiliate of the Company (see Note 8.)

32

RENOVARO INC. AND SUBSIDIARIES
NOTES TO UNAUDITED RESTATED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 — RELATED PARTY TRANSACTIONS (Continued)

The Company currently has a consulting
agreement with Paseco ApS for business advisory services since December of 2019. For the three and nine months ended March 31, 2024 the
Company issued zero and 1,000,000 restricted common shares as payment for services rendered thereunder.

The Company currently has a consulting agreement with
Paseco for business advisory services that commenced in December of 2019. For the three and nine months ended March 31, 2024 the Company
issued zero and 1,000,000 restricted common shares, respectively, for services provided.

The information
set forth above in Note 8—Debt—Notes Payable—Promissory Note relating to the Promissory Note issued to Paseco ApS is
incorporated herein by reference.

NOTE 12 — ACQUISITION

On September
28, 2023, the Company, entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GEDi Cube Intl Ltd.,
a private company formed under the laws of England and Wales (“GEDi Cube”) to acquire 100% of the equity interests
of GEDi Cube from its equity holders (the “Sellers”). On September 28, 2023, the Board of Directors of the Company,
and the board of managers of GEDi Cube unanimously approved the Purchase Agreement and on January 25, 2024, the shareholders of the Company
approved the issuance of the shares of Common Stock pursuant to the Purchase Agreement. The acquisition adds complementary product candidates and technologies
from GEDi Cube and may accelerate the Company's product development and therapeutic approaches for cancer and other diseases.

On February
13, 202